Salivary OMICS factors associated with atopic dermatitis in early infancy
Pediatric Allergy and Immunology · 2026-08 · 37 (8)
DOI: 10.1111/pai.70468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 23.08.2026. Verfasst von Nora Alomeir und 9 weiteren Autor:innen. Beteiligte Einrichtung: Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Saliva. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) often develops in early childhood and may persist into adulthood. Noninvasive measures to identify infants at risk for AD are limited. We investigated whether oral biomarkers and oral microbiota are associated with AD onset within the first 2 years of life.
Methods
In this prospective cohort study, we followed 119 infants residing in Upstate New York from birth to 24 months (2018–2023). AD diagnoses were obtained from electronic health records. Saliva samples were collected at seven time points (1, 2, 4, 6, 12, 18, and 24 months) and analyzed for 5 hormones and 23 cytokines using multiplex immunoassays. Salivary microbiome profiles were characterized via metagenomic sequencing.
Results
Nearly half (48%) of infants developed AD by age 2, with most cases manifesting by 12 months (42%) and peak incidence occurring between months 2–4. Infants who developed AD by 1 year demonstrated significantly elevated estradiol ( p = .007) and progesterone ( p = .046) at 1 month, and a significantly lower salivary cortisol level ( p = .019) at 6 months. Additionally, these infants exhibited higher sIL‐1ra ( p = .024) and IL‐9 ( p = .034) in saliva at 4 months and lower IL‐1α ( p = .038) at 6 months. Salivary microbiome beta diversity differed significantly at 2 months between infants with and without AD by 1 year (p = .038), with lower differential abundances of Bifidobacterium breve and Veillonella atypica in early infancy prior to AD onset.
Conclusion
Early‐life salivary biomarkers, including hormonal, cytokine, and microbiome signatures, may serve as noninvasive indicators of infants at risk for early AD onset. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, New York, USA.
- University of Rochester School of Medicine & Dentistry, Rochester, New York, USA.
- Allendale Columbia School, Rochester, New York, USA.
- Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA.
- Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, USA.
ORCID-Profile: Nora Alomeir, Ellen Chinchilli, Lisa A Beck, Nasser Assery, Julie Ryan Wolf, Jin Xiao, TongTong Wu
Förderung
- NIDCR NIH HHS
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Alomeir, N., Chinchilli, E., Terio, C., Zhang, L., Beck, L. A., Assery, N., Mao, X., Wolf, J. R., Xiao, J., & Wu, T. (2026). Salivary OMICS factors associated with atopic dermatitis in early infancy. Pediatric Allergy and Immunology, 37(8). https://doi.org/10.1111/pai.70468
Vancouver
Alomeir N, Chinchilli E, Terio C, Zhang L, Beck LA, Assery N, et al. Salivary OMICS factors associated with atopic dermatitis in early infancy. Pediatric Allergy and Immunology. 2026;37(8). doi:10.1111/pai.70468
BibTeX
@article{Alomeir2026,
author = {Alomeir, Nora and Chinchilli, Ellen and Terio, Chloe and Zhang, Lanxin and Beck, Lisa A and Assery, Nasser and Mao, Xinyue and Wolf, Julie Ryan and Xiao, Jin and Wu, TongTong},
title = {Salivary OMICS factors associated with atopic dermatitis in early infancy},
journal = {Pediatric Allergy and Immunology},
year = {2026},
volume = {37},
number = {8},
doi = {10.1111/pai.70468}
}
EUVIMED